TNFRSF4 and neoplasm: Because anti-tumor immunity is directed by a dynamic constellation of signals, maximizing the therapeutic benefit of lymphocyte agonists, such as anti-OX40 mAbs, will likely depend on incorporating multiple complementary interventions.